Presentation is loading. Please wait.

Presentation is loading. Please wait.

The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included.

Published byJulio Agüero Modified over 5 years ago

Similar presentations

Presentation on theme: "The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included."— Presentation transcript:

1 The final ultrasound inflammation score (USRA9) for rheumatoid arthritis.
The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included joints/tendon: MCP1, MCP2, MCP3, PIP2, PIP3, radiocarpal joint, ECU tendon, MTP2 and MTP3. All joints included in the USRA9 score are examined with a longitudinal scan on the dorsal side. The extensor carpi ulnaris tendon is examined in a longitudinal and transverse scan. All joints and the tendon are scored 0–3 for GSUS (range 0–54) and PDUS (range 0–54). Not included in the USRA9 (elbow and knee were not included and are not shown). ECU, extensor carpi ulnaris; GSUS, grey-scale ultrasound; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PDUS, power Doppler ultrasound; PIP, proximal interphalangeal; USRA9, Ultrasound in Rheumatoid Arthritis 9 joint/tendon score. Anna-Birgitte Aga et al. RMD Open 2016;2:e000325 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included."

Similar presentations

Figure 2, supplementary online file

Figure 2, supplementary online file
Summary of TB cases across indications and trial periods

Summary of TB cases across indications and trial periods
Main fields of interest.

Main fields of interest.
Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.
(Panel 3a shows the schematic drawing of the individual grades of hypoechoic SH for GS alone. (Panel 3a shows the schematic drawing of the individual grades.

(Panel 3a shows the schematic drawing of the individual grades of hypoechoic SH for GS alone. (Panel 3a shows the schematic drawing of the individual grades.
Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.

Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.
Prevalence of any pathological finding for inflammation (intratendinous or peritendinous inflammatory signal, bone marrow oedema at the painful sites)

Prevalence of any pathological finding for inflammation (intratendinous or peritendinous inflammatory signal, bone marrow oedema at the painful sites)
ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.
The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
MTX-PG concentrations and hepatotoxicity.

MTX-PG concentrations and hepatotoxicity.
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Spectrum of ultrasound grey scale on the dorsal aspects of the wrists ((a) to (d)), MCPs ((e) to (h)), PIPs ((i) to (l)) and MTPs ((m) to (p)): grade 0.

Spectrum of ultrasound grey scale on the dorsal aspects of the wrists ((a) to (d)), MCPs ((e) to (h)), PIPs ((i) to (l)) and MTPs ((m) to (p)): grade 0.
Longitudinal ultrasound image (A) of extensor carpi ulnaris tenosynovitis with prominent areas of anechoic fluid in the tendon sheath (white arrows). Longitudinal.

Longitudinal ultrasound image (A) of extensor carpi ulnaris tenosynovitis with prominent areas of anechoic fluid in the tendon sheath (white arrows). Longitudinal.

Similar presentations

Ads by Google